Cell Death and Disease (Apr 2021)

Impaired AGO2/miR-185-3p/NRP1 axis promotes colorectal cancer metastasis

  • Xisheng Liu,
  • Xiaole Meng,
  • Xiao Peng,
  • Qianlan Yao,
  • Fangming Zhu,
  • Zhongyi Ding,
  • Hongze Sun,
  • Xueni Liu,
  • Dan Li,
  • Ying Lu,
  • Huamei Tang,
  • Bin Li,
  • Zhihai Peng

DOI
https://doi.org/10.1038/s41419-021-03672-1
Journal volume & issue
Vol. 12, no. 4
pp. 1 – 15

Abstract

Read online

Abstract Increasing evidence suggests that global downregulation of miRNA expression is a hallmark of human cancer, potentially due to defects in the miRNA processing machinery. In this study, we found that the protein expression of Argonaute 2 (AGO2), a key regulator of miRNA processing, was downregulated in colorectal cancer (CRC) tissues, which was also consistent with the findings of the Clinical Proteomic Tumor Analysis Consortium (CPTAC). Furthermore, the correlation between the levels of AGO2 and epithelial-mesenchymal transition (EMT) markers (E-cadherin and vimentin) indicated that reduced levels of AGO2 promoted EMT in CRC. Low expression of AGO2 was an indicator of a poor prognosis among CRC patients. Knockdown of AGO2 in CRC cells promoted migration, invasion and metastasis formation in vitro and in vivo but had no influence on proliferation. To provide detailed insight into the regulatory roles of AGO2, we performed integrated transcriptomic, quantitative proteomic and microRNA sequencing (miRNA-seq) analyses of AGO2 knockdown cells and the corresponding wild-type cells and identified neuropilin 1 (NRP1) as a new substrate of AGO2 via miR-185-3p. Our data provided evidence that knockdown of AGO2 resulted in a reduction of miR-185-3p expression, leading to the upregulation of the expression of NRP1, which is a direct target of miR-185-3p, and elevated CRC cell metastatic capacity. Inhibition of NRP1 or treatment with a miR-185-3p mimic successfully rescued the phenotypes of impaired AGO2, which suggested that therapeutically targeting the AGO2/miR-185-3p/NRP1 axis may be a potential treatment approach for CRC.